The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study
Open accessAbstract
Objective : To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy. Design : Observational follow up study of patients with insulin dependent diabetes and nephropathy who had been treated with captopril for a median of 7 years (range 3-9 years). Setting : Outpatient diabetic clinic in a tertiary referral centre. Patients : 35 patients with insulin dependent diabetes and nephropathy were investigated during captopril treatment (median 75 mg/day (range 12.5 to 150 mg/day)) that was in many cases combined with a loop diuretic. 11 patients were homozygous for the deletion allele and 24 were heterozygous or homozygous for the insertion allele of the angiotensin converting enzyme gene. Main outcome measures : Albuminuria, arterial blood pressure, and glomerular filtration rate according to insertion/deletion polymorphism. Results : The two groups had comparable glomerular filtration rate, albuminuria, blood pressure, and haemoglobin A 1c concentration at baseline. Captopril induced nearly the same reduction in mean blood pressure in the two groups—to 103 (SD 5) mm Hg in the group with the deletion and 102 (8) mm Hg in the group with the insertion—and in geometric mean albumin excretion—573 (antilog SE 1.3) μg/min and 470 (1.2) μg/min, respectively. The rate of decline in glomerular filtration rate (linear regression of all glomerular filtration rate measurements during antihypertensive treatment) was significantly steeper in the group homozygous for the double deletion allele than in the other group (mean 5.7 (3.7) ml/min/year and 2.6 (2.8) ml/min/year, respectively; P = 0.01). Multiple linear regression analysis showed that haemoglobin A 1c concentration, albuminuria, and the double deletion genotype independently influenced the sustained rate of decline in glomerular filtration rate (R 2 (adjusted) = 0.51). Conclusion : The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes. Key messages: Determination of the insertion/deletion polymorphism of the angiotensin converting enzyme gene can identify patients with accelerated progression in diabetic nephropathy Inhibition of angiotensin converting enzyme frequently combined with diuretics reduces blood pressure, arrests the progressive rise in albuminuria, and reduces the rate of decline in glomerular filtration rate in diabetic nephropathy The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on progression of diabetic nephropathy Patients with diabetic nephropathy who are homozygous for the deletion polymorphism should be offered earlier and more aggressive antihypertensive treatment with angiotensin converting enzyme inhibitors in addition to strict glycaemic control
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Polymorphisms in Angiotensin-Converting-Enzyme Gene and Progression of Iga Nephropathy
Harden, P. N., Rowe, P. A., Rodger, R. S. C., Junor, B. J. R., Briggs, J. D., Jardine, A. G., Geddes, C., Boulton-Jones, M., Mcllroy, J. H., Connell, J. M. C., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91088-3 · Cited by 215
Cited by
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 560
Staessen, J. A., Wang, J. G., Ginocchio, G., Petrov, V., Saavedra, A. P., Soubrier, F., Vlietinck, R., & Fagard, R. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715120-00059 · Cited by 385
Baboolal, K., Ravine, D., Daniels, J., Williams, N., Holmans, P., Coles, G. A., & Williams, J. D. (1997) · Kidney International · doi:10.1038/ki.1997.373 · Cited by 92
Metadata
- Authors
- Parving, H.-H., Jacobsen, P., Tarnow, L., Rossing, P., Lecerf, L., Poirier, O., & Cambien, F.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1996-09-07
- Volume
- 313
- Issue
- 7057
- Pages
- 591-594
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2005718118
- Cited by
- 185
- References
- 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.